Facilitating Scale-Up and Sustainment of High-Quality Lung Cancer Screening Using the QUILS™ System

QUILS™ SUMMIT

What is the QUILS™-SUMMIT Study?

QUILS™ = Quality Implementation of Lung Cancer Screening

A national randomized trial designed to help lung cancer screening programs (LCSPs) optimize their delivery and outcomes.

Key Questions

Q. Is my LCS program eligible?

Your LCSP is eligible if by Fall 2027 you:

- Are located in the United States
- Have been operating for at least 12 months
- Have conducted at least 25 LDCT scans in the past year
- Have at least 2 team members

Q. What will my site need to do?

- Commit to 24-month active participation after enrollment
- Anticipate conducting at least 25 LDCT scans per year
- Complete four, 30-minute structured interviews over the two-year study implementation period
- Complete 30-minute online surveys at each time point: baseline, 6mos, 12mos, and 24mos
- Upload data to ACR-ELCDR

Q. How will this impact our workflows?

We believe there will be minimal disruption:

- Study designed to fit real-world practice
- No mandated workflow changes required
- Tools and resources available at your own pace

What are the Benefits of Participating?

Resources & Knowledge

- Access to educational resources and expert guidance
- Access to evidence-based implementation strategies
- Networking with lung cancer screening experts
- Potential to receive audit and feedback from QUILS™
- Potential to receive practice facilitation from QUILS™

Practical & Financial Support

- Quality assessment at no cost
- Sites receive 4 implementation stipends of $4,000
- Support for ACR-ELCDR membership and data submission

Quality & Performance

- Potential to improve screening uptake
- Enhances ability to meet quality metrics and CoC accreditation standards

Broader Impact

- Contribution to advancing lung cancer screening nationally

Scan the QR Code to schedule a meeting with the QUILS™-SUMMIT Team

Facilitating Scale-Up and Sustainment of High-Quality Lung Cancer Screening Using the QUILS™ System

QUILS™ SUMMIT

Frequently Asked Questions

Will participating cost our program anything? No. There is no monetary cost to participate. Your site completes a quality assessment, receives educational resources, and a stipend as part of participation.

What if we're not currently in the ACR-ELCDR? No problem! The research team and ACR-ELCDR will provide full support to cover the cost of signing you up to submit data to the ACR-ELCDR.

Can we withdraw if needed? Yes. Participating is voluntary and you may withdraw at any time.

Will our data be kept confidential? Yes. All site data will be de-identified for research purposes and kept secure in a HIPAA-compliant manner.

What happens when the study ends? All sites receive an Implementation, Tailoring, and Sustainment Guidebook developed from this study

Study Timeline

Overall Project: 6 years (Sep 2025 - Aug 2031)
Planning Phase: Years 1-2 (Sep 2025 - Aug 2027)
Intervention Phase*: Years 3-6 (Sep 2027 - Aug 2031)
*Site active participation period

For more information, please contact:
Ameesah Cotten

University of Colorado Cancer Center
summit@cuanschutz.edu

Who's Leading QUILS™-SUMMIT?

Jamie L. Studts, PhD - University of Colorado
Timothy W. Mullett, MD - University of Kentucky
Jennifer R. Knight, DrPH - University of Kentucky

In Partnership With:

- American Cancer Society - National Lung Cancer Roundtable
- American College of Radiology - Lung Cancer Screening Registry (ACR-ELCDR)
- American College of Surgeons - Commission on Cancer (CoC)
- American Lung Association (ALA)
- LUNGevity Foundation

Funded By: National Cancer Institute (NCI) Grant #UG3CA305778

The QUILS™ System